Mirabegron Alternatives Compared
| Mirabegron | Botox (onabotulinumtoxinA) | Oxybutynin |
|
|---|
| Mirabegron | Botox (onabotulinumtoxinA) | Oxybutynin |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Urinary Frequency, Overactive Bladder, Urinary Incontinence, Neurogenic Detrusor Overactivity. Mirabegron may also be used for purposes not listed in this medication guide. |
Prescription only
Botox is approved to treat many conditions, such as chronic migraine, involuntary muscle contractions or twitching, excessive sweating, increased saliva, and overactive bladder to name a few. Botox... View more |
Prescription and OTC
Oxybutynin helps to relieve symptoms of an overactive bladder and urinary incontinence but it may cause side effects such as a dry mouth and constipation. Prescribed for Overactive Bladder... View more |
Related suggestions Urinary Frequency
Urinary Incontinence
Overactive Bladder
Neurogenic Detrusor Overactivity
|
|||||||||||||||||||||||
| More about Mirabegron | More about Botox (onabotulinumtoxinA) | More about Oxybutynin | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mirabegron has an average rating of 4.7 out of 10 from a total of 353 ratings on Drugs.com. 31% of reviewers reported a positive effect, while 51% reported a negative effect. |
Botox has an average rating of 5.7 out of 10 from a total of 473 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 41% reported a negative effect. |
Oxybutynin has an average rating of 6.7 out of 10 from a total of 459 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Mirabegron side effects |
View all Botox side effects |
View all Oxybutynin side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
Lower cost generic |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mirabegron prices |
View all Botox prices |
View all Oxybutynin prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Myrbetriq | Other onabotulinumtoxinA brands include: Botox Cosmetic | Oxytrol, Oxytrol for Women | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
50 hours |
N/A |
2.3 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 250 drugs are known to interact with Mirabegron:
|
A total of 120 drugs are known to interact with Botox:
|
A total of 286 drugs are known to interact with Oxybutynin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
June 28, 2012 |
December 09, 1991 |
July 16, 1975 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.